Cambium Bio

Sydney, Australia

CMT focuses on the development and commercialization of regenerative therapies derived from novel processed human platelets.

$1.9M raised

Dec 2024

Post-IPO Equity

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Cambium Bio raised?

Cambium Bio has raised $1.9M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in December 2024.

Who are Cambium Bio's investors?

Cambium Bio's investors include AventaCell BioMedical, Georgia Research Alliance, Zhengyang Biomedical Technology, Karolis Rosickas.

Where is Cambium Bio headquartered?

Cambium Bio is headquartered in Sydney, Australia.

What does Cambium Bio do?

CMT focuses on the development and commercialization of regenerative therapies derived from novel processed human platelets.

What stage is Cambium Bio at?

Cambium Bio is at the Post-IPO Equity stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated December 5, 2024.

MLA

"Cambium Bio — Funding & Investors." VCBacked, December 5, 2024, https://www.vcbacked.co/company/cambium-bio. Accessed July 3, 2026.

APA

VCBacked. (2024). Cambium Bio — Funding & Investors. Retrieved July 3, 2026, from https://www.vcbacked.co/company/cambium-bio

Wikipedia (cite web)

{{cite web |title=Cambium Bio — Funding & Investors |url=https://www.vcbacked.co/company/cambium-bio |website=VCBacked |access-date=July 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated December 5, 2024.